Health Enhancement Products, Inc. Announces Appointment of John B. Payne as Board Member

BLOOMFIELD HILLS, MI--(Marketwired - Jul 24, 2013) - Michigan-based natural products developer Health Enhancement Products (OTCQB: HEPI) announced today that John B. Payne has agreed to join its board of directors. Mr. Payne has a long and distinguished career in the global animal health industry and is currently serving as Chairman of the Board, American Humane Association -- the nation's leading pioneer in the protection of children and animals. John Payne's appointment to the Board complements the Company's focus on algae-based bioactives targeting animal health applications.

Mr. Payne, who has held top positions at Bayer Healthcare, Mars Global PetCare, and Banfield Pet Hospitals, brings more than 30 years' experience and worldwide recognition for his work to the HEPI board. He was recently honored at the American Humane Association Hero Dog Awards™ for his commitment to bringing "human quality" medicine and healthcare to pets. Zoetis (formerly Pfizer Animal Health) funded the John Payne Veterinary Student Research Initiative, which provided a stipend to a veterinary student researcher as part of the Humane Scholar class of 2012.

Mr. Payne is CEO and Founder of Pet Health Innovations, LLC. He previously served as President and CEO of Banfield Pet Hospitals, the nation's largest private veterinary practice with more than 800 full-service hospitals operating in the United States. As a member of the Mars Global PetCare leadership team based in Brussels, Mr. Payne represented a pet industry market leader with $11 billion in revenues. Prior to Banfield and Mars, Mr. Payne served as President and General Manager of Bayer Healthcare's North American Animal Health Division.

"It is a privilege to serve as a board member of a company dedicated through research to solving complex problems in Animal Health," said Mr. Payne, referring to the Company's rigorous focus on validating its scientific program. The Company's board expressed a similar sentiment.

"We are honored to have John Payne join the board," stated Thomas K. Cox, who recently joined the HEPI board of directors, as well. "His insight and perspective will be invaluable to this company, and having the benefit of his counsel will help propel us forward." Mr. Cox is an attorney and partner at Woodvale Partners, a law firm supporting emerging healthcare businesses, and a Managing Director of Cascade Partners, a Michigan-based private investment firm. Prior to joining the HEPI board in June, Mr. Cox previously held management posts with Seneca Partners and Baxter Healthcare, among others.

The Company continues to make strides in attracting the best scientific, management and technical resources to its ranks -- a dedicated and purposeful effort to establish itself as a leading research-based innovator in animal and human health.

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCQB: HEPI) is a Michigan-based health & wellness company engaged in the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologics for medicinal and pharmaceutical applications in humans and animals. The Company's scientific efforts are focused on the metabolic aspects of oxidation and inflammation, with a parallel program to validate and license products for healthy cholesterol balance.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.